Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,531.00    0.00 (0.00%)
Bid:
1,531.00
Ask:
1,532.00
Spread: 1.00 (0.065%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

17 Dec 2007 14:05

Hikma Pharmaceuticals Plc17 December 2007 For Immediate Release 17 December 2007 Notification of transaction by a Director/PDMR LONDON, 17 December 2007 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of theCompany, has today notified the Company of the sale of 320,000 ordinary sharesof 10 pence each in the capital of the Company, received by him pursuant to anexercise of share options in the Company on 15 October 2007. The sale was made in London at a price of 498.0 pence per share and was executedon 14 December 2007. The shares sold represented 0.187% of the outstanding sharecapital of the Company, and following the sale Mr Darwazah remains interested in1,706,506 ordinary shares, representing 0.999% of the share capital of theCompany. Mr. Darwazah is both a director and a Person Discharging ManagerialResponsibility in respect of the Company, and the above notification relates toDTR 3.1.4R(1)(a) and other Listing Rules. -- ENDS -- Enquiries: Hikma Pharmaceuticals PLC Henry Knowles +44 20 7399 2760 Company Secretary Susan Ringdal +44 20 7399 2760 Investor Relations Director Brunswick Group Jon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and "Generics".Hikma's operations are based principally in the Middle East and North Africa("MENA") region, where it is a market leader and sells across 17 countries, theUnited States and Europe. In 2006, the Group achieved revenues of $317 million(2005 $262 million) and profit attributable to shareholders was $55 million(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. Fornews and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th May 20227:00 amRNSHikma updates Generics guidance for 2022
4th May 20225:58 pmRNSTransaction in Own Shares
3rd May 20226:08 pmRNSTransaction in Own Shares
29th Apr 20225:29 pmRNSTransaction in Own Shares
29th Apr 20225:05 pmRNSCorrection statement re Opiant
29th Apr 20227:15 amRNSTrading Statement
28th Apr 20226:05 pmRNSTransaction in Own Shares
27th Apr 20226:17 pmRNSTransaction in Own Shares
27th Apr 20227:00 amRNSTransaction in Own Shares
25th Apr 20226:04 pmRNSTransaction in Own Shares
25th Apr 20223:42 pmRNSResult of AGM
25th Apr 20227:00 amRNSNotice of GM
22nd Apr 20226:15 pmRNSTransaction in Own Shares
21st Apr 20226:06 pmRNSTransaction in Own Shares
21st Apr 20222:15 pmRNSAcquisition
20th Apr 20225:59 pmRNSTransaction in Own Shares
20th Apr 20227:00 amRNSFTC preliminary approval for Custopharm
19th Apr 20225:49 pmRNSTransaction in Own Shares
14th Apr 20225:35 pmRNSTransaction in Own Shares
13th Apr 20225:19 pmRNSTransaction in Own Shares
12th Apr 20225:55 pmRNSTransaction in Own Shares
12th Apr 20225:49 pmRNSDirector/PDMR Shareholding
11th Apr 20226:09 pmRNSTransaction in Own Shares
11th Apr 20227:00 amRNSShare Buyback Programme
8th Apr 20225:16 pmRNSTransaction in Own Shares
7th Apr 20225:53 pmRNSTransaction in Own Shares
5th Apr 20225:59 pmRNSTransaction in Own Shares
4th Apr 20226:09 pmRNSTransaction in Own Shares
1st Apr 20226:13 pmRNSTransaction in Own Shares
1st Apr 20225:46 pmRNSBlock listing Interim Review
31st Mar 20226:09 pmRNSTransaction in Own Shares
30th Mar 20225:57 pmRNSTransaction in Own Shares
30th Mar 202212:54 pmRNSTransaction in Own Shares
28th Mar 20226:09 pmRNSTransaction in Own Shares
25th Mar 20225:55 pmRNSTransaction in Own Shares
24th Mar 20226:03 pmRNSTransaction in Own Shares
23rd Mar 20225:08 pmRNSTransaction in Own Shares
22nd Mar 20226:03 pmRNSTransaction in Own Shares
21st Mar 20225:58 pmRNSTransaction in Own Shares
18th Mar 20226:32 pmRNSTransaction in Own Shares
17th Mar 20226:03 pmRNSTransaction in Own Shares
17th Mar 202210:00 amRNSAnnual Financial Report
16th Mar 20225:48 pmRNSTransaction in Own Shares
15th Mar 20225:51 pmRNSTransaction in Own Shares
15th Mar 202210:58 amRNSDirector/PDMR Shareholding
14th Mar 20226:23 pmRNSTransaction in Own Shares
11th Mar 20226:11 pmRNSTransaction in Own Shares
10th Mar 20225:48 pmRNSTransaction in Own Shares
9th Mar 20225:53 pmRNSTransaction in Own Shares
8th Mar 20225:21 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.